Israel-Medical-Healthcare

[midastouch017]

Kamada allying with Germany's Pari to develop inhaled drugs
17.1.06 | 15:59 By Tal Levy
Biopharmaceuticals company Kamada has signed a memorandum of understanding with the German company Pari, it announced today. Pari is a world leader inhalation, Kamada said.

The companies will be collaborating on developing and conducting clinical trials of Kamada's Alpha 1-Proteinase Inhibitor, which is being developed to treat hereditary emphysema and cystic fibrosis using inhaled medications.

At present the drugs are administered using needles. Inhalation techniques would be more convenient and cost less, Kamada argues.

Kamada will receive an exclusive license to use Pari's device and the technology associated with developing the inhalation products.

The companies will co-develop at the first stages of clinical trials, with Kamada bearing the drug development costs and the German company carrying the device development costs.

Pari will also supply equipment, spare parts and technical support as needed until the end products are registered with the relevant authorities.

In exchange for the license, Pari will pay royalties on products sold everywhere until the patents expire or ten years from the first commercial sale in each country, whichever is the later.

Kamada's Alpha 1-Proteinase Inhibitor (API) has received orphan drug status in Europe and the U.S. That means that if the two companies are first to successfully complete clinical trials and receive marketing approvals, they will be entitled to exclusive rights, including to marketing, for seven years in the U.S. and ten in Europe.

Kamada CEO David Tsur said the agreement is a commercial and business breakthrough for the company into a new market of administering its drug through inhalation.

http://www.haaretz.com/hasen/spages/671489.html

Dubi